Verastem (VSTM) Amortization of Deferred Charges (2017 - 2026)
Verastem's (VSTM) quarterly Amortization of Deferred Charges came in at -$119000.0 in Q1 2026, down 496.67% year-on-year from $30000.0 in Q1 2025, and down 11800.0% quarter-over-quarter from -$1000.0 in Q2 2025.
Verastem (VSTM) Amortization of Deferred Charges (2017 - 2026) Analysis & Trends
Verastem's Amortization of Deferred Charges history runs 10 years deep, the most recent figure standing at -$119000.0 for Q1 2026.
- On a quarterly basis, Amortization of Deferred Charges fell 496.67% year-over-year to -$119000.0 in Q1 2026; TTM through Mar 2026 was -$120000.0, a 127.03% decrease from a year earlier, with the FY2025 full-year figure at $29000.0, up 680.0% from the prior year.
- Amortization of Deferred Charges fell to -$119000.0 in Q1 2026 per VSTM's latest filing, from -$1000.0 in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $207000.0 in Q4 2024 and bottomed at -$837000.0 in Q4 2023.
- The 5-year median for Amortization of Deferred Charges is $6000.0 (2024), against an average of -$66600.0.
- Across the five-year window, Amortization of Deferred Charges plunged 27800.0% in 2023 and surged 154.18% in 2024, its largest moves.
- Year by year, Amortization of Deferred Charges stood at -$3000.0 in 2022, then plunged by 27800.0% to -$837000.0 in 2023, then soared by 124.73% to $207000.0 in 2024, then slumped by 100.48% to -$1000.0 in 2025, then tumbled by 11800.0% to -$119000.0 in 2026.
- Per Business Quant, the three latest VSTM Amortization of Deferred Charges figures stand at -$119000.0 (Q1 2026), -$1000.0 (Q2 2025), and $30000.0 (Q1 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Verastem | 607.94 Mn | 410.11 Mn | 15.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -119,000.00 |
| Mar 31, 2026 | -119,000.00 |
| Jun 30, 2025 | -1,000.00 |
| Jun 30, 2025 | -1,000.00 |
| Mar 31, 2025 | 30,000.00 |
| Mar 31, 2025 | 30,000.00 |
| Dec 31, 2024 | 207,000.00 |
| Dec 31, 2024 | 207,000.00 |
| Sep 30, 2024 | 201,000.00 |
| Sep 30, 2024 | 201,000.00 |
| Jun 30, 2024 | 6,000.00 |
| Jun 30, 2024 | 6,000.00 |
| Mar 31, 2024 | -419,000.00 |
| Mar 31, 2024 | -419,000.00 |
| Dec 31, 2023 | -837,000.00 |
| Dec 31, 2023 | -837,000.00 |
| Sep 30, 2023 | -371,000.00 |
| Sep 30, 2023 | -371,000.00 |
| Jun 30, 2023 | 112,000.00 |
| Jun 30, 2023 | 112,000.00 |